The Population Science (PS) Program's overall goal is to reduce and prevent morbidity and mortality associated with cancer and its treatment, particularly through identification of genetic and modifiable factors that may influence adverse outcomes. To address this goal, our research is focused around four themes, each of which includes research along the cancer continuum ranging from cancer etiology to cancer treatment outcomes: Nutrition and Chemoprevention;Molecular Epidemiology of Cancer Risk and Prognosis;Cancer Health Disparities;and Tobacco Epidemiology and Translation into Policy. Molecular Epidemiology and Cancer Health Disparities particularly are critical and broadly considered concepts in all themes. The Program members seek to address cancer-related problems that are important to the community that we serve, with outreach, education and interventions to reduce cancer risk and morbidity within our catchment area. The PS program is co-led by Drs. Christine Ambrosone and James Marshall, who together facilitate research in discovery, to identify genetic and environmental causes of cancer and its outcomes; prevention interventions, particularly among those at greatest risk;translation and dissemination to the community;and to ultimately impact policy, particularly related to tobacco. PS seeks to translate basic and clinical science findings to human populations, integrating basic science with cancer epidemiology. PS members include scientists with expertise in each of these areas. Program themes have matured and expanded over the last funding cycle, enhanced by receipt of a number of ROl grants supporting molecular epidemiology of cancer risk and prognosis, disparities research, including POl and U54 grants, ROl and U01-funded dietary interventions, and continued NCI and FDA support for tobacco research. The PS Program is comprised of 22 members from 7 RPCI departments (Cancer Prevention and Control, Health Behavior, Medicine, Surgical !Oncology, Urology, and Dentistry), whose total peer-reviewed funding is $17.4M (NCI funding $12M) and total funding is $22.6M. This compares favorably to $11M peer reviewed/$17M total funding at the time of the last renewal. Of the 4g9 publications generated over the last funding cycle, 28% are intra-programmatic and 15% are inter-programmatic;40 publications were in journals with an Impact Factor >10.

Public Health Relevance

The PS program conducts research to prevent cancer and its precursors, and to reduce morbidity and mortality associated with cancer and its treatment outcomes. Interventions among community and high-risk populations translate findings from the laboratory and observational studies to the community, with a focus on underserved populations in our catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-37
Application #
8738365
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-06-16
Project End
2019-04-30
Budget Start
2014-06-26
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$39,194
Indirect Cost
$15,503
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Hirose, Yuki; Nagahashi, Masayuki; Katsuta, Eriko et al. (2018) Generation of sphingosine-1-phosphate is enhanced in biliary tract cancer patients and is associated with lymphatic metastasis. Sci Rep 8:10814
Vexler, Albert; Yu, Jihnhee; Zhao, Yang et al. (2018) Expected p-values in light of an ROC curve analysis applied to optimal multiple testing procedures. Stat Methods Med Res 27:3560-3576
Mussell, Ashley L; Denson, Kayla E; Shen, He et al. (2018) Loss of KIBRA function activates EGFR signaling by inducing AREG. Oncotarget 9:29975-29984
Yendamuri, Sai; Groman, Adrienne; Miller, Austin et al. (2018) Risk and benefit of neoadjuvant therapy among patients undergoing resection for non-small-cell lung cancer. Eur J Cardiothorac Surg 53:656-663
Kesterson, Joshua P; Szender, J Brian; Schaefer, Eric et al. (2018) Evaluation of Association Between Gynecologic Oncology Fellowship Length and a Career in Academic Medicine. J Cancer Educ 33:141-146
Samuel, Sandeep; Mukherjee, Sarbajit; Ammannagari, Nischala et al. (2018) Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study. PLoS One 13:e0198809
Bhat, Tariq A; Kalathil, Suresh Gopi; Bogner, Paul N et al. (2018) Secondhand Smoke Induces Inflammation and Impairs Immunity to Respiratory Infections. J Immunol 200:2927-2940
Miller, James A; Harris, Kassem; Roche, Charles et al. (2018) Sarcopenia is a predictor of outcomes after lobectomy. J Thorac Dis 10:432-440
Fenstermaker, Robert A; Figel, Sheila A; Qiu, Jingxin et al. (2018) Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo. Clin Cancer Res 24:2642-2652
Qiao, Guanxi; Chen, Minhui; Bucsek, Mark J et al. (2018) Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response. Front Immunol 9:164

Showing the most recent 10 out of 1555 publications